Finkelstein Thompson LLP Announces Investigation of HealthTronics, Inc.

Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of HealthTronics, Inc. (“HealthTronics” or the “Company”) (Nasdaq: HTRN) arising from the Company’s announcement of its intent to merge with Endo Pharmaceuticals Holdings Inc. (“Endo Pharmaceuticals”). Under the terms of the agreement, HealthTronics shareholders will receive $4.85 in cash for every share of HealthTronics stock they own in a transaction valued at approximately $223 million plus the assumption of debt.

The investigation is focused on the potential unfairness of the consideration to HealthTronics’s shareholders and the process by which HealthTronics’s Board of Directors considered and approved the transaction. Indeed, at least one analyst set a price target of $7.00 per share for HealthTronics stock.

If you are interested in discussing your rights as a HealthTronics shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at [phone] or by email at [e-mail].

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.